In patients with prostate cancer with biochemical recurrence following primary therapy, an intensified androgen blockade ...

“The PRO data presented here complements the published clinical efficacy and safety data, add the patient's voice, and ...

The change was made following the submission of a real-world evidence study showing that 5- to 10-year overall survival following robot-assisted radical prostatectomy was comparable to that of ...

"We hope this study encourages a national acceptance of active surveillance as an effective management strategy for prostate cancer,” says Daniel Lin, MD. Long-term data recently published in JAMA ...

Results presented from a phase 1/2 trial of ARV-766 demonstrated efficacy and tolerability in patients whose metastatic castration-resistant prostate cancer progressed after androgen receptor pathway ...

Expert urologist explores potential treatments for BCG-unresponsive intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC), including immune checkpoint inhibitors, oncolytic viral ...

The combination of the oncolytic immunotherapy cretostimogene grenadenorepvec and pembrolizumab (Keytruda) sustained a high complete response (CR) rate in patients with BCG–unresponsive ...

"Since the phase 2 data of the combination therapy of LAE002 (afuresertib) plus LAE001 demonstrated encouraging anti-tumor activity and safety profile in patients with mCRPC, a following phase 3 ...

"Questions that arise for us [include] why, and what's further contributing to our observed outcome?" says Devon M. Langston, MD. In this video, Devon M. Langston, MD, discusses questions raised by ...

Treatment with sacituzumab govitecan (SG; Trodelvy) produced “limited efficacy” in patients with metastatic urothelial carcinoma (mUC) who received prior enfortumab vedotin (EV; Padcev), according to ...

Suspension of treatment in patients with biochemically recurrent (BCR) nonmetastatic hormone-sensitive prostate cancer (nmHSPC) responding well to enzalutamide (Xtandi) regimens had no meaningful ...

“CORE-001’s excellent efficacy, long-term durability of response, and favorable benefit-to-risk-ratio profile seen with combination cretostimogene and pembrolizumab suggest the potential for a novel ...